PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Scope & Guideline

Advancing knowledge in pharmacology and public health.

Introduction

Immerse yourself in the scholarly insights of PHARMACOEPIDEMIOLOGY AND DRUG SAFETY with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN1053-8569
PublisherWILEY
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1992 to 2024
AbbreviationPHARMACOEPIDEM DR S / Pharmacoepidemiol. Drug Saf.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address111 RIVER ST, HOBOKEN 07030-5774, NJ

Aims and Scopes

The journal 'Pharmacoepidemiology and Drug Safety' focuses on the study of the utilization and effects of drugs in large populations, emphasizing the importance of real-world evidence in understanding drug safety and effectiveness. This journal aims to disseminate research that enhances the understanding of drug-related issues in diverse populations, providing insights that can inform clinical practices and regulatory policies.
  1. Real-world evidence and drug utilization studies:
    The journal emphasizes studies that assess the use of medications in real-world settings, providing insights on prescribing patterns, adherence, and the effects of medications on various populations.
  2. Pharmacovigilance and safety monitoring:
    Research on adverse drug reactions and safety monitoring systems is a core focus, aiming to identify and mitigate risks associated with drug use.
  3. Comparative effectiveness research:
    The journal publishes studies comparing the effectiveness of different treatment options, including new therapies versus standard treatments, to inform clinical decision-making.
  4. Methodological advancements in pharmacoepidemiology:
    Papers often explore innovative methodologies for analyzing observational data, including statistical techniques for bias correction and causal inference.
  5. Impact of regulatory interventions:
    The journal frequently features studies evaluating the impact of regulatory changes on drug utilization and safety outcomes, providing critical insights for policymakers.
The journal is witnessing an evolution in its research focus, with several emerging themes gaining traction. These trends reflect the changing landscape of healthcare and the increasing complexity of pharmacotherapy.
  1. Real-world data integration:
    There is a growing emphasis on integrating real-world data from various sources, including electronic health records and claims data, to inform drug safety and effectiveness assessments.
  2. Machine learning and artificial intelligence applications:
    The application of machine learning techniques for predicting treatment outcomes and identifying adverse drug reactions is rapidly trending, showcasing the potential for advanced analytics in pharmacoepidemiology.
  3. Long COVID and its pharmacological implications:
    Research addressing the long-term effects of COVID-19 and the pharmacological treatment of associated symptoms is emerging as a significant theme, driven by the ongoing pandemic.
  4. Patient-centered outcomes and health-related quality of life:
    There is an increasing focus on studies that assess patient-reported outcomes and the impact of medications on quality of life, emphasizing the need for patient-centered approaches in treatment evaluations.
  5. Pharmacogenomics and personalized medicine:
    Research exploring the role of genetic factors in drug response and the tailoring of pharmacotherapy to individual genetic profiles is gaining momentum, reflecting advances in precision medicine.

Declining or Waning

While the journal has maintained a strong focus on various aspects of pharmacoepidemiology, certain themes appear to be declining in prominence based on recent publication trends. This section highlights these waning areas.
  1. Traditional randomized controlled trials (RCTs):
    There seems to be a shift away from traditional RCTs in favor of real-world studies, as researchers increasingly focus on how drugs perform in everyday clinical settings rather than in controlled trial environments.
  2. Basic pharmacokinetic studies:
    Research centered on basic pharmacokinetics is becoming less prominent, with a growing preference for studies that incorporate pharmacogenomics and personalized medicine approaches.
  3. Historical analyses of drug utilization:
    There is a noticeable decline in papers focused on historical drug utilization trends, as the emphasis shifts toward current practices and immediate implications for patient care.
  4. Single-drug studies:
    Studies focusing on the safety and efficacy of single drugs without considering multi-drug interactions or complex treatment regimens are decreasing, reflecting a broader understanding of polypharmacy in patient populations.

Similar Journals

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Connecting Researchers with Cutting-Edge Drug Discoveries
Publisher: WILEYISSN: 0306-5251Frequency: 12 issues/year

British Journal of Clinical Pharmacology, published by Wiley, is a premier peer-reviewed journal that has been at the forefront of pharmacology research since its inception in 1974. Renowned for its high academic rigor, it stands out with an impressive impact factor that places it in the Q1 quartile within both the general pharmacology and medical pharmacology categories. With a Scopus ranking reflecting its esteemed status—ranked #68 out of 272 in medical pharmacology and #109 out of 313 in pharmacology, toxicology, and pharmaceutics—the journal serves as a critical resource for researchers, clinicians, and students who are keen to explore innovations and advancements in drug therapy. The journal's scope encompasses a wide array of topics, including clinical trials, drug safety, and pharmacokinetics, making it an essential platform for disseminating cutting-edge pharmacological findings. Although it does not offer open access, the stringent selection of articles ensures that only the highest-quality research is published, further contributing to the ongoing discourse in clinical pharmacology.

CLINICAL THERAPEUTICS

Exploring the intersection of research and clinical excellence.
Publisher: ELSEVIERISSN: 0149-2918Frequency: 12 issues/year

Clinical Therapeutics, published by Elsevier, is a highly esteemed peer-reviewed journal that has been pivotal in advancing the field of pharmacology since its inception in 1977. With an impressive impact factor and recognition as Q2 in Pharmacology and Q1 in Medical Pharmacology for 2023, it stands at the forefront of research and discussions on innovative therapeutic strategies and pharmacological advancements. This journal not only caters to a broad audience of researchers and clinicians but also plays a vital role in disseminating critical information that supports the enhancement of patient care and safety. As a repository of high-quality, evidence-based articles, Clinical Therapeutics is a crucial resource for those involved in drug development, medical research, and clinical practice, making it an essential read for anyone dedicated to improving health outcomes through pharmaceutical sciences.

JOURNAL OF CLINICAL PHARMACOLOGY

Exploring the Frontiers of Pharmacological Research
Publisher: WILEYISSN: 0091-2700Frequency: 12 issues/year

Welcome to the Journal of Clinical Pharmacology, an esteemed publication in the field of pharmacology and medical pharmacology, published by Wiley. Since its inception in 1973, this journal has been at the forefront of disseminating innovative research findings and comprehensive reviews that enhance our understanding of drug therapies and their clinical applications. With an impact factor that reflects its strong reputation and a Scopus ranking placing it in the 64th percentile among 272 journals in medical pharmacology, the journal stands as a critical resource for researchers, healthcare professionals, and students alike. Although currently not an Open Access journal, it provides invaluable insights into therapeutic drug use and safety, the pharmacokinetics of drugs, and the development of new therapeutic strategies. The journal's commitment to advancing the field through high-quality, peer-reviewed articles ensures it remains a vital asset in the continuously evolving landscape of clinical pharmacology.

THERAPEUTIC DRUG MONITORING

Advancing Pharmacology for Safer, More Effective Therapies
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0163-4356Frequency: 6 issues/year

THERAPEUTIC DRUG MONITORING, published by Lippincott Williams & Wilkins, is a prestigious journal that focuses on the critical area of pharmacology, with a specific emphasis on the therapeutic optimization of drug therapy. With an ISSN of 0163-4356 and an E-ISSN of 1536-3694, this peer-reviewed journal has been contributing valuable research and insights to the field since its inception in 1979. As of 2023, it holds a Q2 classification in the Pharmacology category, indicating its prominent role in advancing pharmaceutical sciences. The journal aims to enhance understanding of drug effectiveness and safety through rigorous studies on drug monitoring and individualized therapy, making it an essential resource for researchers, healthcare professionals, and students dedicated to improving patient care. With its solid standing reflected in Scopus rankings, including a rank of #103 in medical pharmacology and a 62nd percentile, THERAPEUTIC DRUG MONITORING continues to be a vital publication for those aiming to contribute to and stay informed about the latest developments in the field.

CLINICAL PHARMACOLOGY & THERAPEUTICS

Advancing pharmacological knowledge for better patient care.
Publisher: WILEYISSN: 0009-9236Frequency: 6 issues/year

CLINICAL PHARMACOLOGY & THERAPEUTICS, published by WILEY, stands at the forefront of pharmacological research, serving as a pivotal resource for researchers, healthcare professionals, and students in the medical field. With its prestigious Q1 rating in both Pharmacology and Pharmacology (medical) categories, and ranking in the top 4% of journals in the field, it provides cutting-edge insights into drug therapy, pharmacokinetics, and innovative treatment strategies. The journal features a wide range of articles, from original research to comprehensive reviews, all aimed at advancing knowledge and clinical practice in pharmacology. With a publication history dating back to 1960 and continuing through 2024, its commitment to excellence is evident in its robust impact factor and high visibility in the academic community. For professionals striving to stay at the forefront of pharmacological advancements, CLINICAL PHARMACOLOGY & THERAPEUTICS remains an essential platform for disseminating and accessing vital research findings.

INDIAN JOURNAL OF PHARMACOLOGY

Exploring the frontiers of pharmacology since 1978.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0253-7613Frequency: 6 issues/year

INDIAN JOURNAL OF PHARMACOLOGY, published by Wolters Kluwer Medknow Publications, is a premier platform dedicated to advancing the field of pharmacology and its related disciplines. With a rich history since its inception in 1978, this journal aims to disseminate high-quality research findings, reviews, and clinical studies that contribute to the global understanding of drug action and therapeutic practices. As a valuable resource for researchers, professionals, and students alike, it operates within the Q3 quartile of the Pharmacology category, positioning itself as an influential contributor in the realm of medical pharmacology. The journal is committed to publishing rigorous scientific inquiry, fostering innovation, and bridging gaps between laboratory research and clinical application. Readers can access its wide-ranging articles to stay informed about the latest advancements in the field, reflecting its crucial role in shaping future pharmacological research and practice.

PHARMAZIE

Your gateway to cutting-edge pharmaceutical research.
Publisher: AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBHISSN: 0031-7144Frequency: 12 issues/year

PHARMAZIE is a prestigious, peer-reviewed journal published by AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBH, focusing on the dynamic field of pharmaceutical science since its inception in 1947. With its ISSN 0031-7144 and a current impact factor placing it in the Q2 category of Pharmaceutical Science journals, PHARMAZIE has established itself as a pivotal resource for researchers, practitioners, and students alike. The journal emphasizes the dissemination of high-quality, original research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of knowledge and innovation in these fields. While currently not open access, the journal maintains a commendable Scopus rank of #94 out of 183 in its category, highlighting its relevance and appeal to the academic community. With a commitment to bridging the gap between research and practical applications, PHARMAZIE plays a crucial role in shaping the future of pharmaceutical practices and policies.

BRITISH JOURNAL OF PHARMACOLOGY

Elevating research standards in the field of pharmacology.
Publisher: WILEYISSN: 0007-1188Frequency: 24 issues/year

British Journal of Pharmacology is a premier, peer-reviewed journal published by Wiley, specializing in the dynamic field of pharmacology. With a robust impact factor, this journal ranks in the top quartile (Q1) for pharmacology according to the 2023 category rankings, emphasizing its significance and reputation among the global scientific community. As an essential resource for researchers, professionals, and students alike, the journal provides a platform for innovative research spanning foundational studies to clinical applications in pharmacology, toxicology, and pharmaceutics. Since its inception in 1966, the journal has consistently contributed to the advancement of pharmacological science, fostering a deeper understanding of drug action mechanisms and therapeutic advancements. Although primarily subscription-based, the British Journal of Pharmacology is committed to disseminating high-quality research that shapes the future of the field.

Clinical Pharmacology in Drug Development

Bridging research and practice in drug development.
Publisher: WILEYISSN: 2160-7648Frequency: 6 issues/year

Clinical Pharmacology in Drug Development, published by WILEY, is a distinguished journal dedicated to advancing the field of pharmaceutical science and drug development. With a strong commitment to disseminating cutting-edge research, this journal serves as a crucial platform for professionals, researchers, and students aiming to enhance their understanding of pharmacological principles and innovations in medical therapeutics. Since its inception in 2012, the journal has consistently maintained a noteworthy presence in the academic community, currently achieving a Q2 ranking in both Pharmaceutical Science and Medical Pharmacology categories as of 2023. Although the journal operates under a subscription model, it is highly regarded for its rigorous peer-reviewed publications, offering insights into drug efficacy, safety, and regulatory challenges. Positioned at the intersection of clinical practices and pharmaceutical advancements, Clinical Pharmacology in Drug Development plays an essential role in bridging the gap between scientific research and real-world application, ensuring that the latest therapeutic strategies are optimized for patient care.

European Journal of Hospital Pharmacy

Fostering Knowledge for Enhanced Patient Care
Publisher: BMJ PUBLISHING GROUPISSN: 2047-9956Frequency: 6 issues/year

The European Journal of Hospital Pharmacy, published by the prestigious BMJ PUBLISHING GROUP, stands as a vital resource in the field of pharmacy, specifically focused on practices within hospital settings. With its ISSN 2047-9956 and E-ISSN 2047-9964, this journal provides an essential platform for researchers, practitioners, and students to disseminate and access high-quality research that influences clinical practice. Recognized for its significant impact, the journal has achieved a commendable Q2 ranking in both the Pharmacology, Toxicology and Pharmaceutics (miscellaneous) and Pharmacy categories according to Scopus, highlighting its status within the academic community. The journal is indexed among the top 18% in its category, showcasing innovative research and advancements in the field. While the European Journal of Hospital Pharmacy does not operate under an open-access model, its deep commitment to enhancing pharmaceutical care within European hospital settings remains undeterred. The journal also covers a converged period from 2010 to 2024, providing comprehensive insights into evolving practices and challenges. As a premier publication, it plays an essential role in education and professional development, making it indispensable for those involved in pharmacy and healthcare.